

specific embodiments. New claims 21-22 are supported by the specification. Claim 20 has been amended so that it is now dependent on claim 21.

In view of the above, it is respectfully submitted that all claims are in condition for examination. Early action to that end is respectfully requested. The Examiner is hereby invited to contact Steve T. Zelson by telephone at (212) 867-0123 if there are any questions concerning this amendment or application.

Respectfully submitted,

Date:

12/15/99

Cheryl H. Agnis

Cheryl H. Agnis, Reg. No. 34,086
Counsel for

Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6201